Labiana Health (XMAD:LAB) Capex-to-Operating-Income : 0.00 (As of Dec. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Labiana Health's Capital Expenditure for the six months ended in Dec. 2022 was €0.00 Mil. Its Operating Income for the six months ended in Dec. 2022 was €-2.53 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Labiana Health Capex-to-Operating-Income Historical Data

The historical data trend for Labiana Health's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Capex-to-Operating-Income Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Capex-to-Operating-Income

2.68

7.29

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Capex-to-Operating-Income	-	-	-	-

Competitive Comparison of Labiana Health's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labiana Health's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Labiana Health's Capex-to-Operating-Income falls into.

Labiana Health Capex-to-Operating-Income Calculation

Labiana Health's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-5.453)	/	-2.38
	=	N/A

Labiana Health's Capex-to-Operating-Income for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-2.525
	=	N/A

Labiana Health (XMAD:LAB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Labiana Health Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Labiana Health's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Capex-to-Operating-Income

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.